Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor

Medical Oncology

Volumn 25, Issue 1, 2008, Pages 110-112

  Coşkun, Hasan Şenol ^a   Göksu, Sema Sezgin ^a   Şahin, Mehmet ^a   Alanoğlu, Güçhan ^a  

^a SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

CML; Combination chemotherapy; Imatinib

Indexed keywords

BLEOMYCIN; CISPLATIN; COBALT 60; ETOPOSIDE; HYDROXYUREA; IMATINIB; ANTINEOPLASTIC AGENT; BEP PROTOCOL; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEBRILE NEUTROPENIA; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER TOXICITY; MALE; MESENCHYMOMA; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MESENCHYMOMA; PIPERAZINES; PYRIMIDINES;

EID: 42949154402     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0053-5     Document Type: Article

References (12)

1. F Guilhot 2004 Indications for imatinib mesylate therapy and clinical management Oncologist 9 3 271 81
2. R Latagliata M Breccia I Carmosino C Sarlo E Montefusco M Mancini F Natalino A Chistolini R De Cuia E Russo GS Morano F Biondo A Spadea F Mandelli G Alimena 2005 Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment Leuk Res 29 3 287 91
3. H Kantarjian C Sawyers A Hochhaus F Guilhot C Schiffer C Gambacorti-Passerini D Niederwieser D Resta R Capdeville U Zoellner M Talpaz B Druker J Goldman SG O'Brien N Russell T Fischer O Ottmann P Cony-Makhoul T Facon R Stone C Miller M Tallman R Brown M Schuster T Loughran A Gratwohl F Mandelli G Saglio M Lazzarino D Russo M Baccarani E Morra 2002 International STI571 CML study group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 9 645 52
4. CL Sawyers A Hochhaus E Feldman JM Goldman CB Miller OG Ottmann CA Schiffer M Talpaz F Guilhot MW Deininger T Fischer SG O'Brien RM Stone CB Gambacorti-Passerini NH Russell JJ Reiffers TC Shea B Chapuis S Coutre S Tura E Morra RA Larson A Saven C Peschel A Gratwohl F Mandelli M Ben-Am I Gathmann R Capdeville RL Paquette BJ Druker 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 10 3530 9
5. K Yasuhiko A Miyuki T Saburo M Hiroyuki S Yuko H Yoshio F Yusuke 2001 In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Blood 97 1999 2007
6. JR Foringer RR Verani VM Tjia KW Finkel JA Samuels JS Guntupalli 2005 Acute renal failure secondary to imatinib mesylate treatment in prostatecancer Ann Pharmacother 39 12 2136 8 Epub 2005 Nov 15
7. A Schmitt-Graeff A Hochhaus 2006 Hematological side effects of tyrosine kinase inhibition using imatinib Pathologe 27 1 40 6
8. D Rea L Legros E Raffoux X Thomas P Turlure S Maury B Dupriez A Pigneux B Choufi O Reman D Stephane B Royer M Vigier M Ojeda-Uribe C Recher H Dombret F Huguet P Rousselot 2006 Intergroupe francais des leucemies myeloides chronique; Group for research in adult acute lymphoblastic leukemia. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia Leukemia 20 3 400 3
9. B Wassmann H Pfeifer N Goekbuget DW Belen J Beck M Stelljes M Bornhauser A Reichle J Perz R Haas A Ganser M Schmid L Kanz G Lenz M Kaufmann A Binckebanck P Bruck R Reutzel H Gschaidmeier S Schwartz H Hoelzer OG Ottmann 2006 Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph_ALL) Blood 108 5 1469 77
10. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Rea D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lheritier V, Vernant JP, Thomas X, Ifrah N, Dombret H, for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109(4):1408-13.
11. FM Johnson LM Krug HT Tran S Shoaf VG Prieto P Tamboli B Peeples J Patel BS Glisson 2006 Phase I studies of imatinib mesylate combined with cisplatin and irinotecan inpatients with small cell lung carcinoma Cancer 106 2 366 74
12. S George J Desai JP Eder J Manola DP Ryan LJ Appleman GD Demetri 2006 Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumors Eur J Can 42 7 864 70